Nose Cancer Vaccine
Nose Cancer Vaccine
Published on:
20 Oct 2026
0 View
0 View
Hong Kong – Overseas Projects Platform / Signature Project
Hong Kong – Overseas Projects Platform / Signature Project
About this project
Grid's nose cancer vaccine (against EBV) is currently in a Phase 1 clinical trial. The target market is a global opportunity of $31B USD, as validated by Merck's $922.5M and Lilly's $1.55B EBV deal. Grid is targeting Phase 2 and its strategic options.